STRIDES PHARMA SCIENCE Fact Sheet, STRIDES PHARMA SCIENCE Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE Fact Sheet   (PLLB)


One Smallcap Stock: Showing All Signs of a Potential Crorepati Stock


Here is the latest financial fact sheet of STRIDES PHARMA SCIENCE. For more details, see the STRIDES PHARMA SCIENCE quarterly results and STRIDES PHARMA SCIENCE share price and chart. For a sector overview, read our pharmaceuticals sector report.

STRIDES PHARMA SCIENCE Price History

Price Rs 332.3
Mkt Cap Rs m 29,837
Vol '000 78.5
P/E X -8.2
P/CF X 5.3
EPS (TTM) Rs -40.5
1 Day % -2.9
No. of shares m 89.80
1 Week % 7.5
1 Month % 9.8
1 Year % -56.3
52 week H/L Rs 817.5/263.5
As on Jun 27, 2022 (Close)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

STRIDES PHARMA SCIENCE Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
STRIDES PHARMA SCIENCE EQUITY SHARE DATA
High Rs1,2591,1487205471,000 
Low Rs918641334271304 
Sales per share (Unadj.) Rs427.9373.7347.0332.8369.7 
Earnings per share (Unadj.) Rs49.878.341.915.439.6 
Diluted earnings per shareRs49.678.141.815.339.6 
Cash flow per share (Unadj.) Rs72.1100.061.136.462.6 
Dividends per share (Unadj.) Rs4.502.003.0014.002.50 
Adj. dividends per shareRs4.481.992.9913.962.50 
Avg Dividend yield %0.40.20.63.40.4 
Book value per share (Unadj.) Rs306.4274.3294.9281.5309.1 
Adj. book value per shareRs305.1273.3294.1280.8308.7 
Shares outstanding (eoy) m89.4289.5089.5789.5789.68 
Bonus / Rights / Conversions  00000 
Price / Sales ratio x2.52.41.51.21.8 
Avg P/E ratio x21.811.412.626.616.4 
P/CF ratio (eoy) x15.18.98.611.310.4 
Price / Book Value ratio x3.63.31.81.52.1 
Dividend payout %9.02.67.291.06.3 
Avg Mkt Cap Rs m97,33780,03547,19436,64858,465 
No. of employees `000NANANANANA 
Total wages/salary Rs m4,1924,3413,2944,4265,501 
Avg. sales/employee Rs Th00000 
Avg. wages/employee Rs Th00000 
Avg. net profit/employee Rs Th00000 
STRIDES PHARMA SCIENCE INCOME DATA
Net Sales Rs m38,26233,44431,08329,81133,159 
Other income Rs m3,9819,2063,229667734 
Total revenues Rs m42,24342,65034,31230,47833,893 
Gross profit Rs m4,8051,9213,1834,3256,702 
Depreciation Rs m1,9871,9391,7181,8782,063 
Interest Rs m1,8311,9627931,5571,501 
Profit before tax Rs m4,9687,2263,9011,5573,872 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m512214145179317 
Profit after tax Rs m4,4567,0123,7561,3783,555 
Gross profit margin %12.65.710.214.520.2 
Effective tax rate %10.33.03.711.58.2 
Net profit margin %11.621.012.14.610.7 
STRIDES PHARMA SCIENCE BALANCE SHEET DATA
Current assets Rs m37,91824,83630,48723,72128,172 
Current liabilities Rs m31,03918,99326,62225,44927,383 
Net working cap to sales %18.017.512.4-5.82.4 
Current ratio x1.21.31.10.91.0 
Inventory Days Days17597120154165 
Debtors Days Days9596116114122 
Net fixed assets Rs m42,43041,01347,58135,81039,996 
Share capital Rs m894895895896897 
"Free" reserves Rs m26,50523,65125,51624,32126,823 
Net worth Rs m27,40024,54626,41125,21727,719 
Long term debt Rs m16,37715,51318,0656,0398,826 
Total assets Rs m80,34965,84978,06859,53268,168 
Interest coverage x3.74.75.92.03.6 
Debt to equity ratio x0.60.60.70.20.3 
Sales to assets ratio x0.50.50.40.50.5 
Return on assets %7.813.65.84.97.4 
Return on equity %16.328.614.25.512.8 
Return on capital %15.522.910.610.014.7 
Exports to sales %39.439.040.949.351.1 
Imports to sales %00000 
Exports (fob) Rs m15,06713,02712,70814,69416,941 
Imports (cif) Rs m00000 
Fx inflow Rs m16,68415,69714,63016,35135,084 
Fx outflow Rs m659735427352392 
Net fx Rs m16,02514,96214,20315,99934,692 
STRIDES PHARMA SCIENCE CASH FLOW
From Operations Rs m 2,881 1,871 601 2,048 4,814 
From Investments Rs m -6,867 5,826 -1,485 13,062 -5,208 
From Financial Activity Rs m 3,382 -10,157 1,943 -17,094 -158 
Net Cashflow Rs m -5,957 -2,589 1,097 -1,837 -564 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 30.6%
Institution 38.5%
Non-Institution 30.9%
Total 100.0%
Free Float 69.4%
Pledged promoter holdings 56.7%
Shareholding as on Mar 2022
 

Company Information

Regd Off 201 Devavrata, Sector-17, Vashi, Navi Mumbai - 400705
E-mail info@strides.com Web www.strides.com
Tel 022-27892924/3199 Fax 022-27892942
Sector PHARMACEUTICALS Group Private sector
Tr Agent K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.), Karvy Selenium Tower B Plot 31-32, Gachibowli Financial District, Nanakramguda
Auditor Deloitte Haskins & Sells
CHM: Arun Kumar COMP SEC: Manjula Ramamurthy YEAR OF INC: 1990 BSE CODE: 532531 FV (Rs): 10 DIV YIELD (%): 0.8

Read: STRIDES PHARMA SCIENCE 2020-21 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    

Compare STRIDES PHARMA SCIENCE With:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    


Yellow Ad

Advertisement

Our FREE Guide: Small Caps That Will Race Ahead of the Sensex

Richa Agarwal, our head of smallcap research, recently released the updated version of her very popular guide:

'Small Caps That Will Race Ahead of the Sensex':

When you sign-up for Richa's One Stock Crorepati mega summit, you get this premium guide worth Rs 950 for absolutely FREE.:

Learn more



Today's Market

Why Auto Stocks are Rising, the Latest on Cryptos, and Top Buzzing Stocks Today(Pre-Open)

On Monday, Indian share markets rose for the third consecutive session, as prospects of a slowing economic growth fanned hopes that global central banks may go slow on interest rate hikes.

Views on news

The Most Oversold Stocks in India. Is it Finally Time to Get in? (Views On News)

Jan 7, 2022

With the help of relative strength index (RSI), we take a look at top stocks that are oversold at current levels.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks (Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling (Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively? (Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022 Views On News (Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover? (Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - GUJ.INJ(KER) COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS